In our last review of CRISPR Therapeutics (CRSP) on March 23 we were bearish and recommended, "Avoid the long side of CRSP, as the charts and indicators point to the possibility of further steep losses."
More from Investing
The move we're seeing is tough for underinvested bulls that need entry points and even tougher for bears that are trying to fight the strength.
Let's examine the charts and indicators to see if the correction in LRCX has run its course.
I understand and appreciate all the reasons that support a bearish view, but I will follow the price action until it starts to shift.